Yingkun Hou is a seasoned leader in the life sciences sector, currently serving as the Senior Director of Oncology R&D, Strategy & Competitive Intelligence at AstraZeneca since 2024. They previously held the position of Global Portfolio & Strategy Director for Rare Disease at Novo Nordisk, where they focused on new product planning and strategic initiatives. Yingkun has substantial experience from roles at McKinsey & Company, including Associate Partner, where they specialized in corporate strategy, M&A, and commercial strategy. Yingkun's educational background includes a Master of Science in Chemistry with First Class Honours from Imperial College London and an MBA from INSEAD.
Location
London, United Kingdom
This person is not in any offices